AUTHORS
Serhan Unlu, MD, Karol K Gostomczyk2, Vibha Balasubramaniam3, Maxwell Hou, N/A4, Zachary Brady, BS5, Ana Plesca, MD6, Arda Durmaz, PhD7, Akram Abushamma, MD8, Charlotte Zurowski9, Jackson Hensley, N/A10, Luca Guarnera, MD11, Aashray Mandala, BS12, Mark David Orland, MD, PhD13, Nandini Rajaram Siva, MD14, Varun K. Venkatesh, N/A15, Ajitesh Reddy Busireddy, N/A16, Kartik Lakhotiya, MS17, Hari Krishnamurthy18, Vasanth Jayaraman19, Karthik Krishna20, Carmelo Gurnari, MD,PhD21, Carlos Bravo-Perez, MD22, Chantana Polprasert, MD23, Valeria Visconte, PhD24, Jaroslaw P. Maciejewski, MD, PhD, FACP25
AFFILIATIONS
1 Cleveland Clinic, Cleveland, Ohio, United States
2 Cleveland Clinic, Cleveland, Ohio, United States
3 Cleveland Clinic, Cleveland, Ohio, United States
4 Cleveland Clinic, Cleveland, Ohio, United States
5 Cleveland Clinic, Cleveland, Ohio, United States
6 Cleveland Clinic, Cleveland, Ohio, United States
7 Cleveland Clinic, Cleveland, Ohio, United States
8 Cleveland Clinic, Cleveland, Ohio, United States
9 Cleveland Clinic, Cleveland, Ohio, United States
10 Cleveland Clinic, Cleveland, Ohio, United States
11 Cleveland Clinic, Cleveland, Ohio, United States, University of Rome Tor Vergata, Rome, Italy
12 Cleveland Clinic, Cleveland, Ohio, United States
13 Cleveland Clinic, Cleveland, Ohio, United States
14 Cleveland Clinic, Cleveland, Ohio, United States
15 Cleveland Clinic, Cleveland, Ohio, United States
16 Cleveland Clinic, Cleveland, Ohio, United States
17 Cleveland Clinic, Cleveland, Ohio, United States
18 Vibrant Sciences, Santa Clara, California, United States
19 Vibrant Sciences, Santa Clara, California, United States
20 Vibrant Sciences, Santa Clara, California, United States
21 Cleveland Clinic, Cleveland, Ohio, United States, University of Rome Tor Vergata, Rome, Italy
22 Cleveland Clinic, Cleveland, Ohio, United States, Hospital Universitario Morales Meseguer, Murcia, Spain
23 Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand
24 Cleveland Clinic, Cleveland, Ohio, United States
25 Cleveland Clinic, Cleveland, Ohio, United States
ABSTRACT
Introduction
Etiopathogenesis of aplastic anemia (AA) might involve a sufficiently rare combination of underlying genetic aberrations and pathogenic immune triggers. Molecular mimicry through viral infections being central inciting events is one such hypothesis, as viral antigens were recently shown to be recognized by cytotoxic T-cells that also target hematopoietic stem cells in a subset of AA patients. [PMID: 38277625] However, not all patients with AA have serological evidence of infection with culprit viruses, and seropositivity to human derived antigens in aplastic anemia patients have also been documented. [PMID: 35927326] Whether these human derived antigens are cross reactive with a molecular target on hematopoietic stem cells or loss of self-tolerance is mediated through another mechanism remains elusive.
We previously applied a high density protein and peptide array to sera of AA and other BMFS patients and discovered a unique signal in AA patients not detected in other BMFS patients or healthy controls; anti-RNA polymerase III (POLR3A) reactivity. In our previous analysis, 49% of AA patients had a signal of POLR3A autoantibodies, classically found in around 10% of systemic sclerosis patients and is associated with increased risk of cancer and renal crisis. A separate analysis of patients with autoimmune conditions and POLR3A seropositivity showed cytopenias to be more frequent in seropositive patients. PNH clones were more likely to be present in seropositive AA patients, and response to IST seemed to be orthogonal to POLR3A status. Findings were validated with western blot, and a semi-randomly generated array of 801,064 peptides, of which 5 were 100% homologous to POLR3A. [Blood, 2025. 146:4977] In this study, we confirmed our findings with ELISA, and validated specificity of prior findings with disease controls with other autoimmune conditions.
Aims
Validate anti-POLR3A antibody as a biomarker in AA as a serological assay, analyze correlation with disease state, treatment types, response to treatment, and any underlying patient characteristics.
Results
Sera of newly diagnosed, refractory, relapsed, and in remission AA patients (n=165) were tested with a high density protein array targeting 56 human antigens, anti-POLR3A signal was the only uniquely positive marker. Large granular lymphocytic leukemia (LGLL, n=83), rheumatoid arthritis (RA, n=38), Sjogren (n=81) were used as disease controls, in addition to 120 healthy controls. Seropositivity of POLR3A in AA was 37%, 13% in RA, and 1.2% in Sjogren syndrome. None of the LGLL or HC had seropositivity to POLR3A. Results were confirmed in sera of 85 AA patients with ELISA, with a seropositivity rate of 13% (n=11). Median age of seropositive and seronegative AA patients was 54 and 47 years, respectively (p=0.26). Only 10% of male and 15.6% of female patients were positive (p=0.53). Seropositivity in sAA (13.8%, n=4) was similar to mAA (13.2%, n=7). In total, 64 patients with PNH were tested, including 13 with PNH without AA. Seropositivity rate of primary PNH was 15% (n=2), while in AA with PNH, seropositivity rate was 10.7% (n=6). Size of PNH clone was not correlated with seropositivity, or the signal intensity. Of 2 sera collected at initial presentation, one patient was seropositive. Of 9 patients who had relapsed disease, seropositivity rate was 44% (n=4), and 18% (n=2/11) in refractory disease. Seropositivity rate of patients in remission was 4% (n=2/50) (p=0.0038 for relapsed and p=0.14 for refractory).
In a separate analysis, we compared the sequence of peptides homologous to POLR3A to known viral sequences, and found that AEETLEALILKE, which had a signal in 13% of patients, was homologous to E2 protein of HPV, with 88% homology.
Conclusion
POLR3A is ubiquitously present in all human cells, and is associated with autoimmune conditions, including systemic sclerosis and idiopathic pulmonary fibrosis. Large scale high density protein array studies have shown that seropositivity is uniquely present in AA patients, which was confirmed by ELISA. Seropositivity was not related to baseline patient characteristics or disease severity, however, was more frequent in relapsed disease compared to those in remission. Further research is needed to describe the mechanism of autoimmunity against this ubiquitously present antigen and how it relates to etiopathogenesis of AA, including not previously described viral antigens as possible sources of molecular mimicry.
DISCLOSURES
Serhan Unlu, MD: No relevant conflicts of interest to declare.